Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly FCF Margin of 30.17% in Q3 2025, up 94.42% quarter-over-quarter from 540.86% in Q2 2025, and up 85436.0% on a YoY basis from N/an in Q3 2024.
Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' FCF Margin history runs 6 years deep, the most recent figure standing at 30.17% for Q3 2025.
- In Q3 2025, FCF Margin rose 85436.0% year-over-year to 30.17%; the TTM figure through Sep 2025 stood at 48.16% (up 316524.0% YoY), while the FY2024 annual figure was 216.65%, changed N/A from the prior year.
- FCF Margin was 30.17% for Q3 2025 at Cyclerion Therapeutics, up from 540.86% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 19.93% in Q4 2024 to a low of 23314.52% in Q1 2021.
- Historically, FCF Margin has averaged 3215.02% across 4 years, with a median of 1195.06% in 2025.
- The sharpest annual moves came in 2021 and 2022: FCF Margin plunged 2043296 bps in 2021, then surged 2150931 bps in 2022.
- A 4-year view of FCF Margin shows it stood at 1619.14% in 2021, then sank by 118 bps to 3535.29% in 2022, then soared by 101 bps to 19.93% in 2024, then sank by 251 bps to 30.17% in 2025.
- The last three FCF Margin figures came in at 30.17% (Q3 2025), 540.86% (Q2 2025), and 1195.06% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Cyclerion Therapeutics | 11.50 Mn | 8.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.17% |
| Jun 30, 2025 | -540.86% |
| Mar 31, 2025 | -1,195.06% |
| Dec 31, 2024 | 19.93% |
| Sep 30, 2024 | -884.54% |
| Jun 30, 2022 | -3,535.29% |
| Mar 31, 2022 | -1,805.20% |
| Dec 31, 2021 | -1,619.14% |
| Sep 30, 2021 | -2,276.72% |
| Jun 30, 2021 | -183.63% |
| Mar 31, 2021 | -23,314.52% |
| Dec 31, 2020 | -10,583.46% |
| Sep 30, 2020 | -4,132.00% |
| Jun 30, 2020 | -1,894.66% |
| Mar 31, 2020 | -2,881.56% |
| Dec 31, 2019 | -1,508.24% |
| Sep 30, 2019 | -1,750.00% |
| Jun 30, 2019 | -1,610.32% |